[Medulloblastoma: analysis of 14 cases treated at the J. Bordet Institute and literature review].
Between 1966 and 1986, 14 patients with histologically verified cerebellar medulloblastomas were seen at J. Bordet Institute after total (4 cases) or partial (10 cases) tumor removal. Twelve received postoperative irradiation after some courses of chemotherapy (Vincristine, Procarbazine, Methotrexate) for 5. In 10 cases the X ray treatment was given to the whole cerebrospinal axis with approximately 50 Gy delivered to the primary tumor site, 25-35 Gy to the remaining brain and spinal cord. As in other series of the literature the long term prognosis is not too good, with approximately 50% of the patients surviving more than 5 years. Failure at the primary site happened in 4 cases. As a consequence of the small number of patients treated, no conclusion can be drawn from risk factor analysis. Yet it appears that younger patients fared better than older ones. A detailed description of the side effects of the treatment is therefore given for the five children treated at prepubertal age: some growth impairment seems to be the rule, a consequence of GH deficiency--if not compensated--and of the direct effect of ionizing radiation on the vertebral bodies. While discussing the progress of neurosurgery and radiotherapy for the treatment of medulloblastoma, the authors emphasize the need of more efficient adjuvant chemotherapy regimens and the interest of multicenter trial for evaluating them.
Ismaili
K
K
Hôpital Universitaire des Enfants, Reine Fabiola.
Sariban
E
E
Otten
J
J
Regnier
R
R
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002528:Cerebellar Neoplasms / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy / Q000209:etiology; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D008875:Middle Aged; D010902:Pituitary Gland / Q000528:radiation effects; D011379:Prognosis; D011879:Radiotherapy Dosage
D013006:Growth Hormone
Le médulloblastome: analyse de 14 cas traités à l'Institut J. Bordet et revue de la littérature.